title: [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
abstract: BACKGROUND
  Secondary coronary prevention with lipid lowering drugs have become a major issue in health policy formulation due to the large upfront investment in drug therapy. The recently completed LIPID trial with pravastatin in secondary prevention immediately raise the question whether pravastatin might be cost-effective in Switzerland.
  
  
  METHODS
  We conducted a cost-effectiveness analysis from the perspective of third party payers. The following costs were included in the analysis: daily treatment costs of pravastatin, non fatal myocardial infarction, coronary bypass operations and stroke. Life years gained was obtained by applying the declining exponential approximation of life expectancy. All calculations were standardized to 1000 treated patients.
  
  
  RESULTS
  The net costs of treating 1000 patients (i.e. drug costs minus the costs of sequelae and interventions) are Fr. 3.6 Mio. In addition, a total of 430 life-years may be saved through treatment. The corresponding cost-effectiveness of pravastatin treatment is Fr. 8341 (nominal) Fr. 6985 (discounted).
  
  
  CONCLUSIONS
  The results suggest that the cost-effectiveness of pravastatin in secondary prevention lie well within the threshold of other commonly accepted medical interventions and may be considered an economically viable approach for secondary coronary prevention.
authors.affiliation: Abteilung Medizinische Okonomie, Universitätsspital Zürich.
authors.forename: T D
authors.initials: TD
authors.lastname: Szucs
authors.forename: O
authors.initials: O
authors.lastname: Bertel
authors.forename: R
authors.initials: R
authors.lastname: Darioli
authors.forename: F
authors.initials: F
authors.lastname: Gutzwiller
authors.forename: R
authors.initials: R
authors.lastname: Mordasini
mesh_terms: D000789:Angina, Unstable / Q000191:economics* / Q000401:mortality / Q000517:prevention & control; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D008297:Male; D009203:Myocardial Infarction / Q000191:economics* / Q000401:mortality / Q000517:prevention & control; D017035:Pravastatin / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D012008:Recurrence
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin